Key result
Inhaled nitrous oxide significantly reduced VAS scores for anxiety (10 vs 58 mm, P<0.05) and discomfort (18 vs 45 mm, P<0.01) compared to intravenous nalbuphine during atrial flutter ablation.
Why the study?
Does inhaled nitrous oxide reduce anxiety and discomfort compared to intravenous nalbuphine in patients undergoing radiofrequency ablation for atrial flutter?
RCT (n=76)
Prospective randomized
Does inhaled nitrous oxide reduce anxiety and discomfort compared to intravenous nalbuphine in patients undergoing radiofrequency ablation for atrial flutter?
Inhaled nitrous oxide is an effective alternative to intravenous nalbuphine for reducing anxiety and discomfort during radiofrequency ablation of atrial flutter, offering better symptom control and less hypotension despite a higher rate of vomiting.
Supports nitrous oxide as opioid-sparing sedation for atrial flutter ablation; extends periprocedural comfort options in electrophysiology.
BACKGROUND: In patients with common atrial flutter (CAF), radiofrequency ablation (RFA) causes discomfort. Patients undergoing RFA often feel pain which is difficult to control as the mechanisms are unclear. HYPOTHESIS: Inhaled nitrous oxide (N2O) is a potent sedative-analgesic-anxiolytic agent that may relieve anxiety and discomfort during CAF ablation. METHODS AND RESULTS: In a prospective randomized study, the effect of Inhaled N2O was compared with that of intravenous sedation with Nalbuphine during CAF ablation in 76 patients (64 +/- 13 years, 56 men). We used a 24 pole mapping catheter around the tricuspid annulus and a 8-mm tip ablation catheter for each patient. Forty-two patients (group 1) underwent radiofrequency (RF) application to the cavotricuspid isthmus 5 minutes after the beginning of inhalation of a (50% N2O/50% O2) mixture. Thirty-four patients (group 2), underwent the first RF application 15 minutes after the end of an infusion of Nalbuphine (20 mg delivered over 15 minutes). Ablation-related anxiety and discomfort were assessed using a visual analog scale (VAS) ranging from 0 to 100 mm, with 0 correlating to the statement "no pain at all" and 100 with "the worst possible pain." The VAS score was determined at the end of each application. The number of RF applications (group 1; 10 +/- 8 vs group 2; 11 +/- 6, P = NS) and procedure duration (group 1; 75 +/- 53 minutes vs group 2; 72 +/- 45 minutes, P = NS), were similar for the two groups. N(2)O sedation compared with nalbuphine infusion reduced VAS for anxiety (10 mm +/- 8 vs 58 mm +/- 22, P < 0.05) and for discomfort (18 mm +/- 9 vs 45 mm +/- 34, P < 0.01), respectively. Although there was more frequent vomiting in group 1; 7 of 42 (17%) than in group 2; 3 of 34 (9%), P < 0.05, patients were less likely to have hypotension during the procedure 1 of 42 (2.5%) versus 4 of 34 (12%), P < 0.05, respectively. CONCLUSION: Inhalation of a (50% N2O/50% O2) mixture during RF ablation for atrial flutter is a safe and efficient way to reduce anxiety and discomfort caused by RF applications.
No takes yet. Share an insight, caveat, or question.
Laurent et al. (2006) conducted an RCT in Common atrial flutter (n=76). Inhaled nitrous oxide vs. Intravenous Nalbuphine (20 mg over 15 minutes) was evaluated on VAS score for anxiety (p=< 0.05). Inhaled nitrous oxide significantly reduced VAS scores for anxiety (10 vs 58 mm, P<0.05) and discomfort (18 vs 45 mm, P<0.01) compared to intravenous nalbuphine during atrial flutter ablation.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: